Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
(Adnkronos) – SHANGHAI, Sept. 13, 2023 /PRNewswire/ — Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as “Bioray”) announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name:
